Actively Recruiting
Al18F-HER2-BCH PET in Breast Patients Treated With ADC Therapy
Led by Peking University Cancer Hospital & Institute · Updated on 2026-05-13
50
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
Sponsors
P
Peking University Cancer Hospital & Institute
Lead Sponsor
T
The Affiliated Hospital of Qingdao University
Collaborating Sponsor
AI-Summary
What this Trial Is About
To use the molecular PET radionuclide (F-18) labelled HER2 Affibody to evaluate the predictive and prognostic value in breast patients treated with ADC therapy
CONDITIONS
Official Title
Al18F-HER2-BCH PET in Breast Patients Treated With ADC Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 618 years old; ECOG 0 or 1
- Patients with HER2 positive or low tumors
- Receiving neoadjuvant therapy
- Adequate cardiac, bone marrow, renal, hepatic and blood clotting functions
- Life expectancy greater than 3 months
You will not qualify if you...
- Significant hepatic or renal dysfunction
- Pregnant or planning to become pregnant
- Unable to remain still for half an hour
- Refused to participate in the clinical research
- Suffering from claustrophobia or other mental disorders
- Any other situation that researchers consider unsuitable for participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University Cancer Hospital & Institute
Beijing, China, 100142
Actively Recruiting
Research Team
X
Xiaoyi Guo, PhD
CONTACT
Y
Yannan Yuan
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SCREENING
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here